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OBJECTIVE — Attempts to build an artiﬁcial pancreas by using subcutaneous insulin deliv-
ery from a portable pump guided by an subcutaneous glucose sensor have encountered delays
andvariabilityofinsulinabsorption.Wetestedclosed-loopintraperitonealinsulininfusionfrom
an implanted pump driven by an subcutaneous glucose sensor via a proportional-integral-
derivative (PID) algorithm.
RESEARCH DESIGN AND METHODS — Two-day closed-loop therapy (except for a
15-min premeal manual bolus) was compared with a 1-day control phase with intraperitoneal
open-loop insulin delivery, according to randomized order, in a hospital setting in eight type 1
diabetic patients treated by implanted pumps. The percentage of time spent with blood glucose
in the 4.4–6.6 mmol/l range was the primary end point.
RESULTS — During the closed-loop phases, the mean  SEM percentage of time spent with
bloodglucoseinthe4.4–6.6mmol/lrangewassigniﬁcantlyhigher(39.14.5vs.27.76.2%,
P  0.05), and overall dispersion of blood glucose values was reduced among patients. Better
closed-loop glucose control came from the time periods excluding the two early postprandial
hours with a higher percentage of time in the 4.4–6.6 mmol/l range (46.3  5.3 vs. 28.6  7.4,
P  0.025) and lower mean blood glucose levels (6.9  0.3 vs. 7.9  0.6 mmol/l, P  0.036).
Timespentwithbloodglucose3.3mmol/lwaslowandsimilarforbothinvestigationalphases.
CONCLUSIONS — Our results demonstrate the feasibility of intraperitoneal insulin deliv-
ery for an artiﬁcial -cell and support the need for further study. Moreover, according to a
semiautomated mode, the features of the premeal bolus in terms of timing and amount warrant
further research.
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n patients with type 1 diabetes, the
near-normal glucose control required
to prevent long-term complications
(1,2) remains difﬁcult to achieve (3). In-
deed, the incidence of hypoglycemia in-
creases when glucose control approaches
normal glucose levels (4). For this reason
the development of an “artiﬁcial pan-
creas”hasbeenagoalfor30years(5,6).
An artiﬁcial -cell requires three ele-
ments: a continuous insulin delivery de-
vice, a continuous glucose monitoring
system, and a control algorithm linking
insulin delivery to glucose measurements
(3,7,8). The recent development of better
performing continuous glucose sensors
renewed the potential feasibility of
closed-loop insulin delivery (9–11).
Short-term initiatives in the clinical re-
search setting were reported in recent
years but showed some limitations (12–
14).Keylimitingfactorswere,ﬁrst,delays
inthemodulationofinsulinactionrelated
to subcutaneous infusion and, second,
time lags in glucose detection due to ei-
ther the placement of the sensors in the
interstitial compartment of subcutaneous
tissue or the internal structure of im-
planted intravenous sensors (15). To re-
duce glucose deviations at mealtimes, a
hybrid option of closed-loop insulin de-
livery includes a manual priming bolus
(16).
Reported beneﬁts of intraperitoneal
insulin infusion from implantable pumps
include fast insulin action and low basal
plasma insulin levels, resulting in tight
glucose control and a low incidence of
hypoglycemic events (17). The feasibility
ofautomatedclosed-loopinsulindelivery
from implantable pumps has been dem-
onstrated in clinical trials performed with
the Long-Term Sensor System, which
coupled these devices with an intrave-
nous glucose sensor (18).
Our approach to optimize closed-
loop glucose control includes the use of
closer to physiological intraperitoneal in-
sulin delivery, subcutaneous glucose
sensing, and a proportional-integral-
derivative (PID) algorithm with a manual
premeal bolus, resulting in a hybrid PID
(HyPID) system. The objective of this
study was to test the feasibility of such an
approach. We investigated patients in the
same controlled hospital setting while
testing the HyPID system and when fol-
lowing their usual self-management. This
approachmarksadifferencefromthepre-
viouslyreportedclosed-looptrials,which
considered home-use periods for com-
parison with in-clinic closed-loop studies
(13,16).
RESEARCH DESIGN AND
METHODS— Eight patients with
type 1 diabetes, treated by an implanted
pump using intraperitoneal delivery
(model MMT-2007D; Medtronic Diabe-
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regular insulin (Insuplant; sanoﬁ-aventis,
Paris, France) for at least 3 months, were
enrolled. Inclusion criteria were the fol-
lowing: age 18–70 years, insulin delivery
within 15% of expected accuracy for the
60 days preceding the trial, plasma anti-
insulinantibodylevel30%accordingto
aradioimmunoassayoffreeandtotalanti-
insulin antibody using a technique adapted
from that of Palmer et al. (19), written in-
formed consent, and health insurance cov-
erage by the French Social Security System.
Exclusion criteria were pregnancy, breast
feeding, plasma creatinine 150 mol/l,
serum alanine aminotransferase and aspar-
tate aminotransferase above twice the
highest limit of the normal range, total
blood Hb 12 g/dl, any cardiovascular
eventduringthelast6months,anyevolv-
ing ischemic or proliferative diabetic ret-
inopathy on eye fundus examination for
the previous year, and any known or sus-
pected allergy to glucose sensor com-
ponents.
The study protocol was approved by
the regional ethics committee Comite ´d e
ProtectiondesPersonnesSudMediterrane ´e
IV, Montpellier, France, on 11 September
2007. The study was authorized by Agence
Franc ¸aise de Se ´curite ´ Sanitaire des Produits
de Sante ´ on 29 November 2007 and regis-
tered under the reference number 2007-
A00696-47 (www.afssaps.sante.fr).
Subjects were admitted to the hos-
pital for a total of 86 h, which was di-
vided into a preparation phase (14 h), a
control (open-loop) phase (24 h), and a
closed-loop phase (48 h). The order of
the control and closed-loop phases was
randomized.
At admission (day 1, 1800), two sub-
cutaneous glucose sensors (Medtronic
Diabetes), similar to those used in
Medtronic’s CGMS and Guardian RT sys-
tems, were inserted in the abdominal area
and were calibrated against a capillary
bloodglucose(CBG)value2hafterinser-
tion and then every 4 h. The second sen-
sor was used as a backup in case the ﬁrst
sensor failed to track glucose. At 2000,
patients were instructed to program their
insulin bolus for dinner and to remain
fasting until the following morning. On
day 2, 20 min before the 800 experiment
start, an intravenous catheter was placed
in an antecubital vein for frequent blood
sampling. Blood samples were then
drawn(forlaterbloodglucoseandplasma
insulin measurements) every 20 min at
the start of each meal for a period of 2 h
(800–1000, 1300–1500, and 1900–
2100, considered as “early postprandial
periods” for breakfast including 40 g car-
bohydrate and lunch and dinner both in-
cluding 70 g carbohydrate), every hour
from 800 to 2200 except for early post-
prandialperiods,andevery2hfrom2200
to 800 (considered as “nonpostprandial
periods”).
During the 24-h control phase, the
patients were instructed to monitor their
diabetes by seven CBG tests performed
before and 2 h after each meal and at bed-
time and to program their pump accord-
ing to the self-monitoring data. Sensor
glucose data were monitored in real time
and were patient blinded.
During the 48-h closed-loop phase,
the pump’s insulin infusion rate was au-
tomatically modulated according to the
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Figure1—Correlationsbetweenmeasured(lab)andalgorithm-estimated(model)plasmainsulinlevelsduringtheclosed-loopphasesineachofthe
eight type 1 diabetic patients investigated by the HyPID system.
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lin delivery rate were monitored in real
time and were patient blinded. Fifteen
minutes before meals, a manually pro-
grammed insulin bolus, consisting of
30% of the amount the patient would
have programmed according to premeal
blood glucose levels and meal carbohy-
drate content, was delivered.
For safety purposes, CBG tests were
also performed every hour from 800 to
2200 and every 2 hours from 2200 to
800. In addition, each time the sensor
glucose value decreased to 4.4 mmol/l
(80 mg/dl) or increased to 13.2 mmol/l
(240 mg/dl) and when patients reported
symptoms of suspected hypoglycemia, a
CBG test was performed. It should be
noted that procedures to respond to hy-
poglycemia and sustained hyperglycemia
were also followed during the control
phase, although at home the subject
might not have such close monitoring.
System considerations
The closed-loop system is made up of
three components: a subcutaneous glu-
cose sensor, the insulin delivery algo-
rithm (running on a laptop computer),
and the intraperitoneal insulin infusion
pump.Thecomputerreceivessensordata
using a radiofrequency protocol and
sends commands to the pump using the
Bluetooth protocol. A modiﬁed personal
pump communicator, set up to receive
commands from a Bluetooth adapter, was
used instead of the personal pump com-
municatorusedbythepatient.Thepump
was then set to the minimum allowed
basal infusion rate of 0.2 unit/h, with the
algorithm delivering discrete 0.2-unit bo-
lusesascalculatedbasedonreal-timesen-
sor glucose measurements.
The mathematical algorithm used to
calculate the insulin delivery rate is based
on a model of the multiphasic insulin re-
sponseofa-cell(20).Theﬁrstversionof
this algorithm was described in Steil et al.
(13). The version used in this study fur-
ther incorporates the effect of insulin-
inhibiting insulin secretion (i.e., insulin
feedback) (21). The equations describing
the model are
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12IPn
 2 
1  11  2
Kd
IBn  2,
where u(n) is the insulin infusion rate cal-
culated at time step n (which is every 1
min),andthenotation(n1)denotesthe
previous time step. The algorithm is
tuned with the parameters KP, 
I, 
D, and
	 and with 1, 2, and Kcl corresponding
to the intraperitoneal insulin absorption
kinetics. The term 	IP corresponds to the
inhibition by plasma insulin concentra-
tion on the delivery of insulin. Because
the pump can only deliver insulin as sin-
gle 0.2-unit boluses, the amount actually
delivered by the pump (IB) is used to cal-
culate the estimated plasma insulin con-
centration. The tuning parameters are
individualized for each subject as a func-
tion of his or her total daily insulin dose.
The target glucose level used for the algo-
rithm was 100 mg/dl (5.5 mmol/l).
Laboratory measurements
Plasma glucose concentrations were mea-
sured by hexokinase assay (Olympus,
Rungis, France). CBG measurements
were performed using OneTouch Ultra
meters and strips (LifeScan, Milpitas,
CA). Plasma insulin was measured by a
speciﬁc insulin assay (bi-insulin immu-
noradiometric assay; Schering CIS bio in-
ternational, Gif sur Yvette, France).
Assessment of glucose control
Theprimaryendpointwasthepercentage
of time spent with blood glucose in the
4.4–6.6 mmol/l range. All analyses were
done by using the laboratory blood glu-
cose measurements unless otherwise
noted.Secondaryendpointsincludedthe
same index for the early postprandial pe-
riods and for the nonpostprandial peri-
ods; mean blood glucose for the overall
experiment,fortheearlypostprandialpe-
riods, and for the nonpostprandial peri-
ods; and percentage of time spent with
blood glucose 3.3 mmol/l and 10
mmol/l.
Statistical analysis
Results are expressed as arithmetic
means  SEM or SD when speciﬁed and
95% CIs of differences. Means were com-
pared using the Wilcoxon signed-rank
test. The level of signiﬁcance was set at
P  0.05. Calculations and statistical
analysis were performed using SYSTAT
10 (SPSS, Chicago, IL).
RESULTS— Eight patients (seven
male and one female) were enrolled. Pa-
tient characteristics were as follows
(mean  SD): age 59.8  8.7 years, BMI
26.4  3.4 kg/m
2, diabetes duration
31.7  15.1 years, treatment duration by
implanted pump 8.5  7.4 years, A1C
6.8  1.0%, and daily insulin require-
ment 0.60  0.21 units   kg
–1   day
–1.
Sensor accuracy
Mean and median relative absolute differ-
ences ( SD) between paired sensor and
laboratory blood glucose values were
15.9  3.8 and 13.9  2.9%, respec-
tively, which are consistent with previous
reports (16).
Insulin delivery and algorithm
assessment
The correlation coefﬁcient (R
2) between
the measured and algorithm-estimated
plasma-insulin levels was 0.730  0.067.
Data for each patient are shown in Fig. 1.
In general, although the magnitude of the
estimated levels is higher than that of the
measuredlevels,thekineticsobservedare
well described by the model. The ob-
served difference in the slope of the esti-
mates versus the predictions may be due
to speciﬁc aspects of intraperitoneal insu-
lin infusion.
Glucose control during control and
closed-loop periods
The distribution of blood glucose values
and the mean blood glucose and plasma
insulin levels are presented in Table 1. A
signiﬁcantly higher percentage of time
was spent between 4.4 and 6.6 mmol/l
during closed-loop versus control phases
(39.1  4.5 vs. 27.7  6.2%, P  0.05),
although mean blood glucose shows no
Figure2—Bloodglucoselevels(mean95%CI)duringclosed-loop(continuouslines)andcontrol
(dashed lines) phases in the eight type 1 diabetic patients investigated by the HyPID system. A:
from 2200 to 0800. B: From 1 h before to 5 h after meal start.
Closed-loop intraperitoneal insulin delivery
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nomenon was detected.
Tighter control was obtained for
closed-loop phases in nonpostprandial
periods, in which both mean blood glu-
cose level and percentage of time spent
with blood glucose between 4.4 and 6.6
mmol/l are signiﬁcantly better. In con-
trast, early postprandial glucose control
was similar during closed-loop and con-
trol periods. Of note, plasma insulin
levels were signiﬁcantly higher in non-
postprandial periods but signiﬁcantly
lower in early postprandial periods dur-
ing closed-loop phases.
In the nighttime period between
2200 and 800, mean blood glucose lev-
els and percentage of time spent be-
tween 4.4 and 6.6 mmol/l were similar
(Fig. 2A). A trend to better control was
observed only from 2200 to 200 during
closed-loop phases (6.2  0.4 vs. 7.9 
0.9mmol/l,P  0.069).Dataanalysisin
early postprandial periods showed sim-
ilar glucose peak levels and time-to-
glucose peak (Fig. 2B). However, for
closed-loop phases, plasma insulin
peak levels were signiﬁcantly lower
(29.7  2.9 vs. 51.5  8.4 mIU/l, P 
0.017) and the time to the plasma insu-
lin peak was longer (79.9  7.2 vs.
38.3  7.2 min, P  0.012). These dif-
ferences were observed similarly with
all three main meals (data not shown).
Figure 3 indicates the higher mean
frequency of blood glucose between 4.4
and 6.6 mmol/l during closed-loop
phases.Italsoshowsatighterinterpatient
distribution of glucose values in these
phases.
In terms of safety, 13 glucose devia-
tions 4.4 mmol/l were detected by the
patients through suggestive symptoms
and/oridentiﬁedearlybytheglucosesen-
sors during closed-loop phases, and 3
were detected during control phases. All
events occurred in nonpostprandial peri-
ods. Of note, after oral glucose adminis-
tration (10 g on average), a trend for
earlier correction of blood glucose was
observed during closed-loop phases
(82.67  0.81 vs. 70.33  0.19 mg/dl
after 20 min).
CONCLUSIONS— Our study dem-
onstrates the feasibility of closed-loop in-
sulin delivery by means of implanted
insulin pumps using the intraperitoneal
route and driven by subcutaneous glu-
cose sensors and a PID algorithm. Inter-
estingly, time spent in the near-normal
glucose range is increased in comparison
with that for open-loop use of this insulin
therapy based on self-monitoring data
andpatientinitiativeinthesameenviron-
mental conditions.
The improved glucose control ob-
tained during the closed-loop phases rep-
resents a valuable improvement for
patients whose glucose was already well
controlled as indicated by their initial
A1C levels of 6.8  1.0%, because it was
achievedwithminimalpatientinteraction
with the system. The assessment of
closed-loop effectiveness, measured by
percentageoftimespentinthetightnear-
normal glucose range, illustrates the use-
fulness of sensor- and algorithm-driven
insulin infusion. Because hyperglycemic
excursions have been associated with ox-
idative stress (22) and hypoglycemic de-
viations impair quality of life and can
promote hypoglycemia unawareness,
leading to the occurrence of severe hypo-
Figure 3—Cumulative distribution of blood glucose values during closed-loop and control (open-loop) phases in the eight type 1 diabetic patients
investigated by the HyPID system. Individual data are presented as thin continuous lines during closed-loop phases and as thin dashed lines during
control (open-loop) phases. Thick lines indicate the median cohort distributions of blood glucose values. Vertical red dotted lines denote the glucose
range between 4.4 (80) and 6.6 (120) mmol/l (mg/dl).
Renard and Associates
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closed-loop system is to reduce glucose
deviations. In addition, reduced interpa-
tientvariabilityofglucoselevelsalsomer-
its notice. This result is valuable in terms
of reproducibility and safety of the
algorithm.
The main beneﬁt on glucose control
during closed-loop phases was observed
in time periods excluding the early post-
prandial (2-h) periods. Improvement of
glucose control during these periods ap-
pears to be driven mainly by higher
plasma insulin levels obtained by algo-
rithm-driven insulin delivery. The trend
toaquickerreturntopremealglucoselev-
els in the late postprandial periods, i.e.,
2 h after meals, can be highlighted.
However,despitethemanualdeliveryofa
premealbolusduringclosed-loopphases,
the early postprandial period remains a
challenging situation that also was not
solved in previously reported closed-loop
experiments (14,15).
Programming a manual bolus before
meals did not seem to be as effective in
our study as in a recent trial using contin-
uous subcutaneous insulin infusion (16).
Ofnote,inourexperiments,postprandial
insulin peaks were lower and later during
closed-loopversuscontrolphases.Repro-
duction of the dynamics of the physiolog-
ical ﬁrst phase of insulin secretion would
require reaching higher acute plasma in-
sulinlevelscorrespondingbothtothe“ce-
phalic phase” of insulin secretion and to
the “incretin-promoted” component
(24,25).Futureclinicaltrialsshouldeval-
uatetheamountandtimingofthemanual
premeal bolus to better mimic physiol-
ogy. From an algorithmic consideration,
we can speculate that insulin action re-
sulting from the premeal bolus may mask
the appearance of glucose, therefore de-
laying the increase in the insulin delivery
rate by the algorithm.
Blood glucose could be maintained
between 3.85 and 10 mmol/l for 85% of
the time in a recently reported 24-h
closed-loop trial performed on eight ado-
lescent type 1 diabetic patients in a hos-
pital setting by combining subcutaneous
insulin infusion, subcutaneous sensing,
and a PID algorithm, the two latter ele-
ments being very similar to ours, except
that insulin feedback was included in our
algorithm (16). Glucose control was
maintainedinthesamerangeonly58%of
the time in the open-loop phase per-
formed in the home environment. Our
data show that blood glucose was kept
between 4.4 and 10 mmol/l for 76.5% of
the time in 48-h closed-loop phases,
whichwasalsosigniﬁcantlybetterthanin
the open-loop phases during which glu-
cosewaskeptinthesamerangefor63.7%
of the time. The evaluation of the open-
loop period in the same hospital setting
has, however, a stronger value for com-
parison. The large between-patient vari-
ability of glucose control, during per-
formance of the closed-loop trial using
subcutaneous insulin delivery reported
by the authors, may represent a signiﬁ-
cant difference with our data obtained by
intraperitoneal infusion (16). This differ-
ence in terms of blood glucose variability
may be partially due to differences be-
tweenthesetworoutesofinsulindelivery,
which has already been reported in previ-
ous studies assessing implantable insulin
pumps (17).
Hypoglycemia is a worrisome situa-
tion in closed-loop insulin delivery. In
our study, hypoglycemic deviations oc-
curred in a limited percentage of time,
whichwasnotsigniﬁcantlydifferentfrom
thatinthecontrolphase.Thisobservation
argues for the safety of the algorithm
used. Moreover, because all hypoglyce-
miceventswereeitherdetectedbythepa-
tients from suggestive symptoms and/or
immediately identiﬁed by the sensor, we
may expect that a low-glucose warning
system based on the sensor signal would
be sufﬁcient to prevent severe hypoglyce-
mia in patients using the closed-loop al-
gorithm at home.
In summary, our study demonstrates
the feasibility, safety, and beneﬁts on glu-
cose control of a new alternative for
closed-loop control. The reduced be-
tween-patient variability in glucose
control is also worth noting. Although
currently limited to a few patients in
whom subcutaneous insulin delivery was
considered unreliable, implanted devices
for intraperitoneal insulin infusion have
beenshowntoprovideadditionalbeneﬁts
in terms of quality of life (17). Further
development is needed to improve early
postprandial glucose control, requiring
premeal manual intervention for bolus
programminginagreementwithprevious
trials (12,16).
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